热门资讯> 正文

Minerva Neurosciences GAAP每股收益为-25.51美元

2026-03-11 19:12

米勒娃科学(NERV) 0

Minerva Neurosciences press release (NERV): Q4 GAAP EPS of -$25.51.
Cash, cash equivalents and restricted cash at December 31, 2025 were approximately $82.4 million, as compared to $21.5 million at December 31, 2024. The increase in cash and cash equivalents during the period resulted from the October 2025 private placement.

More on Minerva Neurosciences

Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia - Slideshow
Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript
Seeking Alpha’s Quant Rating on Minerva Neurosciences
Historical earnings data for Minerva Neurosciences
Financial information for Minerva Neurosciences

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。